Compounds > 3,4-methylenedioxy-3',4',5'-trimethoxy chalcone
Page last updated: 2024-11-12

3,4-methylenedioxy-3',4',5'-trimethoxy chalcone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID10291089
CHEMBL ID276600
SCHEMBL ID3173761
SCHEMBL ID3173746
MeSH IDM0514149

Synonyms (20)

Synonym
2-propen-1-one, 3-(1,3-benzodioxol-5-yl)-1-(3,4,5-trimethoxyphenyl)-, (2e)-
(e)-3-(1,3-benzodioxol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
CHEMBL276600 ,
AKOS002322215
209158-91-8
F3328-0010
(e)-3-(benzo[d][1,3]dioxol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
SCHEMBL3173761
SCHEMBL3173746
VU0610928-1
bdbm50477591
JGVTZQYRMQWZQO-GQCTYLIASA-N
(e)-1-(3,4-methylenedioxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-1-en-3-one
3-(1,3-benzodioxol-5-yl)-1-(3,4,5-trimethoxyphenyl)-2-propen-1-one
6tnm489mva ,
3-(1,3-benzodioxol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one, (e)-
unii-6tnm489mva
dmu135
dmu-135
Z46059983
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Integrase Human immunodeficiency virus 1IC50 (µMol)100.00000.00051.544310.0000AID308045; AID308046
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID409994Inhibition of Mycobacterium tuberculosis recombinant protein tyrosine phosphatase assessed as enzyme activity at 25 uM2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Synthetic chalcones as efficient inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase PtpA.
AID247566Antiproliferative activity against human cancer SNB-78 cell line2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID247832Antiproliferative activity against human Colon cancer HT-29 cell line; Not Tested2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID247628Antiproliferative activity against human colon cancer HCT-15 cell line2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID247513Antiproliferative activity against human SIHA cell line2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID247572Antiproliferative activity against human cancer OVCAR-5 cell line2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID247851Antiproliferative activity against human colon cancer SW-620 cell line; Not Tested2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID247563Antiproliferative activity against human cancer DU-145 cell line2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID247564Antiproliferative activity against human cancer HOP-62 cell line2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID308045Inhibition of HIV1 integrase strand transfer activity2007Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14
Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore.
AID247573Antiproliferative activity against prostate cancer PC-3 cell line2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID247554Antiproliferative activity against human cancer A-549 cell line2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID247555Antiproliferative activity against human cancer Hep-2 cell line2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID452430Antiproliferative activity against human K562 cells after 5 days by MTT assay2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity.
AID94656Compound was evaluated for cytotoxic activity against K562 human chronic myelogenous leukemia cell line using MTT assay1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Potent antimitotic and cell growth inhibitory properties of substituted chalcones.
AID247739Antiproliferative activity against human cancer SKOV-3 cell line; Not Tested2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID308046Inhibition of HIV1 integrase 3'-end processing activity2007Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14
Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's4 (80.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.03 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
methotrexate
[no description available]		2.0510dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
chalcone
trans-chalcone : The trans-isomer of chalcone.		2.0510chalconeEC 3.2.1.1 (alpha-amylase) inhibitor
4-hydroxycinnamoylmethane
4-hydroxycinnamoylmethane: RN given refers to cpd without isomeric designation. p-hydroxyphenylbut-3-ene-2-one : An enone in which a 4-hydroxyphenyl group is attached to the beta-carbon atom of but-3-en-2-one.		1.9910
fosbretabulin
[no description available]		2.0510stilbenoid
2,4,2'-trihydroxychalcone
2,4,2'-trihydroxychalcone: structure in first source		2.0310
metochalcone
metochalcone: structure		2.0510
3',4',5',3,4,5-hexamethoxy-chalcone
[no description available]		2.4420
mdl 27048
MDL 27048: structure given in first source; powerful & reversible microtubule inhibitor		2.4220
combretastatin a-4 disodium phosphate
[no description available]		2.0510
3-hydroxy-4,3',4',5'-tetramethoxychalcone
3-hydroxy-4,3',4',5'-tetramethoxychalcone: structure in first source		2.4220
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		02.0210
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0210
Koch's Disease
[description not available]		02.0410
Tuberculosis
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.		02.0410